Exploring Three Low-Beta Stocks for Stable Returns Exploring Three Low-Beta Stocks for Stable Returns

Photo of author

By Ronald Tech

The Allure of Low-Beta Stocks

Beta measures a stock’s volatility compared to a benchmark, like the S&P 500 Index.

Stocks with a beta above 1.0 are more volatile, while those below 1.0 offer stability.

Investing in low-beta stocks can add a defensive element to portfolios, balancing risk profiles.

Stocks in Focus

Unum Group (UNM)

Unum Group offers various insurance services and has seen increased earnings expectations leading to a Zacks Rank #1 (Strong Buy).

Investors can benefit from a 2.8% annual yield on UNM shares, with a robust 6.2% five-year annualized dividend growth rate.

Elevance Health (ELV)

Elevance Health supports healthier lives through health benefits, boasting a Zacks Rank #2 (Buy) amid positive earnings trends.

The latest quarterly results showed strong performance with earnings and sales beating estimates.

Interactive Brokers (IBKR)

Interactive Brokers operates as a global electronic market maker with positive analyst revisions, earning a Zacks Rank #2 (Buy).

Anticipate upcoming earnings growth with the stock outperforming the S&P 500 over the past two years.

The Potential of Low-Beta Stocks

Low-beta stocks, like IBKR, ELV, and UNM, contribute to stable portfolios with their defensive nature.

By blending these stocks with high-beta counterparts, investors can achieve a balanced risk mix.

Furthermore, the favorable Zacks Ranks on these stocks reflect analysts’ optimism.


See also  3 Stock Spinoffs Poised for Market Domination
The Forgotten Gold Mine: Hidden Value in Spinoff Stocks

Spinoff stocks have long been cast aside by investors, deemed as unwanted remnants of bigger entities. However, diving deep into the world of spinoffs reveals a treasure trove waiting to be discovered. As investing guru Joel Greenblatt highlights in his timeless masterpiece "You Can Be a Stock Market Genius," these castaways often harbor unrealized potential when set free.

Solventum (SOLV): A Diamond in the Rough

Solventum (NYSE:SOLV) emerges as a promising player in the healthcare landscape after being spun off from industrial giant 3M (NYSE:MMM). With a stronghold in sterilization devices, dressings, tapes, this $8.2 billion revenue giant is ready to conquer. Despite a sluggish start post-separation, boasting revenues of $2 billion and $2.08 per share earnings, the stock remains undervalued. Priced at a discount due to an $8.3 billion debt burden from its previous parent, Solventum is on the path to redemption, making it a beacon in the sea of mediocrity.

Kenvue (KVUE): Unleashing Consumer Power

Kenvue (NYSE:KVUE) struts into the consumer health sector post its emancipation from Johnson & Johnson (NYSE:JNJ). The custodian of iconic brands like Tylenol, Listerine, or Band-Aid, this $15 billion powerhouse flexes its muscles. With a formidable dividend legacy inherited from its erstwhile parent, Kenvue stands tall despite a 24% drop since its inception. Like a phoenix rising from the ashes, Kenvue is poised to soar high on the wings of trust and quality.

W.K. Kellogg (KLG): A Breakfast of Champions

If you had cereal for breakfast, chances are it bore the imprint of W.K. Kellogg (KLG). Stepping out of the shadows of its parent, this stalwart in the breakfast food industry is no stranger to your morning routine. With a legacy as rich as your favorite cornflakes, W.K. Kellogg is a stock to watch, destined to nurture portfolios much like it nurtures bodies.

The Rise of W.K. Kellogg in a Shrinking Cereal Market The Rise of W.K. Kellogg in a Shrinking Cereal Market